Autolus Therapeutics plc ADR (NASDAQ: AUTL) on Monday, plunged -3.04% from the previous trading day, before settling in for the closing price of $5.60. Within the past 52 weeks, AUTL’s price has moved between $1.61 and $7.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 152.23%. The company achieved an average annual earnings per share of 38.73%. With a float of $147.97 million, this company’s outstanding shares have now reached $174.10 million.
The extent of productivity of a business whose workforce counts for 463 workers is very important to gauge.
Autolus Therapeutics plc ADR (AUTL) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Autolus Therapeutics plc ADR is 15.01%, while institutional ownership is 60.91%.
Autolus Therapeutics plc ADR (AUTL) Latest Financial update
As on 12/30/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.45 earnings per share (EPS) for the period falling under the consensus outlook (set at -$0.25) by -$0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 38.73% per share during the next fiscal year.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Autolus Therapeutics plc ADR (AUTL) is currently performing well based on its current performance indicators. A quick ratio of 6.11 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 556.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.20, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.54 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
The latest stats from [Autolus Therapeutics plc ADR, AUTL] show that its last 5-days average volume of 0.96 million was inferior to 1.58 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 14.05%. Additionally, its Average True Range was 0.39.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 53.99%, which indicates a significant increase from 12.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.20% in the past 14 days, which was lower than the 74.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.08, while its 200-day Moving Average is $4.25. Now, the first resistance to watch is $5.65. This is followed by the second major resistance level at $5.87. The third major resistance level sits at $6.06. If the price goes on to break the first support level at $5.23, it is likely to go to the next support level at $5.04. The third support level lies at $4.82 if the price breaches the second support level.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
Market capitalization of the company is 945.36 million based on 265,926K outstanding shares. Right now, sales total 1,700 K and income totals -208,380 K. The company made 410 K in profit during its latest quarter, and -45,850 K in sales during its previous quarter.
